The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
A lanthanide‐catalyzed intermolecular hydroamination of 2‐alkynylbenzonitriles with secondary amines has been disclosed, providing a streamlined access to a range of aminoisoindoles in moderate to excellent yields. The salient features of this reaction include high bond‐formation efficiency, mild reaction conditions, 100 % atomic efficiency and good functional group tolerance. This methodology has
Alkynylation‐Desilylation‐Alkynylation‐Cycloisomerization (ADAC) Three‐Component Synthesis of 2,2′‐Biindolyls – Concise Synthesis of Tjipanazole I
作者:Sebastian Kustosz、Patrik Niesobski、Thomas J. J. Müller
DOI:10.1002/cctc.202001607
日期:2021.1.12
three‐component reaction using TIPS‐butadiyne as a four carbon building block gives a rapid and efficient access to 2,2′‐biindolyls in a one‐pot fashion. This facile entry to unsymmetrically substituted title compounds has been employed in a concise two‐step synthesis of the alga alkaloid tjipanazole I.
The invention is concerned with the compounds of formula I:
and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R
1
-R
6
are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
The invention is concerned with the compounds of formula I:
and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.